Adial Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ADIL Nasdaq 2830 www.adial.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply - Jun 25th, 2025 6:30 am
Top Midday Decliners - Jun 17th, 2025 12:50 pm
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering - Jun 17th, 2025 6:00 am
Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting - Jun 16th, 2025 6:00 am
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04 - Jun 11th, 2025 6:00 am
EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial - Jun 11th, 2025 5:30 am
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - May 15th, 2025 6:30 am
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study - May 13th, 2025 6:30 am
Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration - May 8th, 2025 6:30 am
EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program - May 8th, 2025 6:02 am
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds - May 2nd, 2025 9:48 am
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders - May 1st, 2025 6:30 am
EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders - May 1st, 2025 6:02 am
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update - Mar 4th, 2025 6:30 am
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04 - Feb 25th, 2025 7:00 am
EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder - Feb 25th, 2025 6:30 am
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies - Feb 19th, 2025 7:00 am
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - Feb 12th, 2025 7:00 am
EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - Feb 12th, 2025 6:30 am
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - Jan 29th, 2025 7:00 am